Amylyx Announces $5 Million Series A Financing to Support Phase II Clinical Trial of AMX0035 for Treatment of Amyotrophic Lateral Sclerosis

They will join directors Dr. George Milne, former President of Central Research and President of Strategic ... Amylyx is developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the ...